Comparative Pharmacology
Head-to-head clinical analysis: CYCLOPHOSPHAMIDE versus GLEOSTINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOPHOSPHAMIDE versus GLEOSTINE.
CYCLOPHOSPHAMIDE vs GLEOSTINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to cell cycle nonspecific cytotoxicity. It requires hepatic metabolism by cytochrome P450 (CYP2B6, CYP3A4, CYP2C9) to form active metabolites, phosphoramide mustard and acrolein, which alkylate DNA and inhibit protein synthesis.
GLEOSTINE (lomustine) is a nitrosourea alkylating agent that crosslinks DNA and RNA, inhibiting DNA synthesis and repair. It is cell cycle phase-nonspecific.
400-600 mg/m2 IV every 2-4 weeks; or 50-100 mg/m2 orally daily for 7-14 days; or 1-2 g/m2 IV as a single dose every 3-4 weeks.
130 mg/m2 orally every 6 weeks as a single dose; alternatively, 75 mg/m2 orally every 3 weeks.
None Documented
None Documented
Clinical Note
moderateCyclophosphamide + Verteporfin
"Cyclophosphamide may increase the cardiotoxic activities of Verteporfin."
Clinical Note
moderateCyclophosphamide + Digoxin
"Cyclophosphamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCyclophosphamide + Digitoxin
"Cyclophosphamide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCyclophosphamide + Deslanoside
Terminal elimination half-life: 4-8 hours in adults with normal renal function; prolonged in renal impairment (up to 15 hours) and in children.
16-48 hours (terminal), with an active metabolite half-life of up to 5 days, requiring dose adjustment for renal impairment
Renal: approximately 30-60% of dose excreted unchanged in urine; biliary/fecal excretion is minimal (<5%).
Renal: 60% (as metabolites), Fecal: <5% (unchanged and metabolites), Biliary: minimal
Category D/X
Category C
Alkylating Agent
Alkylating Agent
"Cyclophosphamide may decrease the cardiotoxic activities of Deslanoside."